Analyst Allen Lutz from Bank of America Securities maintained a Buy rating on Healthequity and keeping the price target at $125.00.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Allen Lutz has given his Buy rating due to a combination of factors that highlight HealthEquity’s strategic initiatives and market opportunities. The company has recently launched a platform that connects Health Savings Account (HSA) members with telehealth services, specifically focusing on GLP-1 weight management medications. This initiative allows members to use their HSA funds for these services, which are not covered by insurance, potentially increasing consumer savings and driving demand in a high-spend healthcare category.
Additionally, HealthEquity has introduced a direct HSA enrollment platform, anticipating regulatory changes that could expand HSA eligibility. This move into the direct-to-consumer (DTC) space is seen as a positive step towards increasing awareness and adoption of HSAs, despite the unclear immediate financial impact. The company’s efforts to enhance its digital platform and engage with the ACA marketplace suggest a forward-looking strategy that could benefit its market position over time. As a result, Lutz maintains a positive outlook on HealthEquity’s potential for growth and innovation in the evolving healthcare landscape.
In another report released yesterday, TR | OpenAI – 4o also reiterated a Buy rating on the stock with a $104.00 price target.
Based on the recent corporate insider activity of 61 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of HQY in relation to earlier this year.